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OBJECTIVES The purpose of this study was to assess the extent to which hypertrophic cardiomyopathy
(HCM) exists unsuspected and undetected in the general population.
BACKGROUND Hypertrophic cardiomyopathy is a disease with diverse natural history for which the potential
to produce adverse consequences has been emphasized. However, the possibility of this
disease remaining clinically dormant for many years has not been as widely appreciated.
Certainly, the clinical recognition of previously undiagnosed patients with HCM may be
advantageous by permitting risk stratification for sudden cardiac death or for timely
pharmacologic therapy when symptoms intervene.
METHODS We prospectively conducted an echocardiographic survey in 64 primarily rural communities
within Minnesota (populations ,10,000) over a 33-month period.
RESULTS A total of 15,137 echocardiograms were performed at the request of primary care physicians
for the purpose of excluding cardiovascular abnormalities. Hypertrophic cardiomyopathy was
identified in 44 patients during the survey (0.29%), and 29 of these patients (0.19% of the
15,137 echocardiograms) had not been previously identified as having cardiac disease or
HCM. At diagnosis, ages were 16 to 87 years (mean 57); 14 patients were $60 years of age,
and only two were ,30 years. Twenty-four patients (83%) had either no or only mild or
transient symptoms; 5 (17%) evidenced severe functional limitation; in eight patients the
onset of symptoms had been deferred until $70 years of age. Basal left ventricular outflow
obstruction (gradients 20 to 82 mm Hg) was evident in 11 patients (38%). Relatively mild
phenotypic expression of the disease was substantiated by localized patterns of left ventricular
wall thickening occurring more commonly than diffusely distributed hypertrophy (48% vs.
7%, respectively), and electrocardiograms that were frequently normal (about 25%) and rarely
showed evidence of left ventricular hypertrophy (10%).
CONCLUSIONS These prospectively assembled data show that HCM may remain clinically dormant and
undetected within community-based rural populations for many years (often to advanced
ages) with a not inconsequential prevalence similar to that of HCM in the general population.
(J Am Coll Cardiol 1999;33:1590–5) © 1999 by the American College of Cardiology
Hypertrophic cardiomyopathy (HCM) is a primary and
heterogeneous cardiac disease that may result in premature
cardiovascular death, but is also consistent with normal
longevity with little or no disability (1–10). The extent to
which HCM can remain clinically occult and undetected for
many years remains unresolved (6–10). Indeed, the occur-
rence of unsuspected HCM in the general population has
recently been reported to be 0.17% (about 1:500) (11),
suggesting that this disease may be more common than
previously thought. However, many of the clinical data
available in HCM have been generated from a few tertiary
referral centers in urban settings, largely comprising highly
selected and preferentially referred patient populations
(1,2,12,13). Therefore, in the present study, we took advan-
tage of a unique circumstance at our institution in which
echocardiographic services are routinely performed in rural
areas of Minnesota (and Wisconsin) for patients suspected
of having cardiac disease. This circumstance permitted us to
prospectively assemble data relevant to the occurrence and
clinical profile of HCM in community-based rural popula-
tions.
METHODS
Patient selection. The present data acquisition took ad-
vantage of a long-standing outreach cardiology program
administered by the Minneapolis Heart Institute. Mobile
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vans equipped with two-dimensional echocardiographic in-
struments systematically make scheduled visits on request to
64 primary care nonspecialty clinics, offices and hospitals
(which are without echocardiographic capability), to per-
form diagnostic studies. These echocardiographic studies
are performed on a daily basis largely in rural regions
throughout Minnesota and also Wisconsin (primarily com-
munities of ,10,000 in population). Patients at these sites
were scheduled in advance for complete diagnostic echocar-
diographic studies for the purpose of excluding cardiovas-
cular abnormalities, at the discretion of primary care phy-
sicians, general internists, pediatricians and occasionally
clinicians with training specifically in cardiovascular dis-
eases.
The present study represents a prospectively conducted
survey of echocardiographic studies obtained at all outreach
sites over the 33-month period from December 1993 to
March 1996. This diagnostic echocardiography program
involved 30 Minnesota counties with a combined popula-
tion of 2,700,000 constituting 60% of the overall state
population. Also included were five adjacent counties in
Western Wisconsin with a combined population of
190,000. Studies were performed by six highly experienced
echocardiography technicians (cumulative 75 years of imag-
ing experience), each of whom had received specific advance
training focused on recognition of the HCM phenotype
(14,15). Those echocardiographic studies that were judged
on site to be potentially diagnostic or suggestive of HCM
were subsequently reviewed by the senior investigator
(B.J.M.) in Minneapolis.
Echocardiography. Echocardiographic studies were per-
formed with commercially available Hewlett-Packard Sonos
1000 or 2000 series instruments using 2.5-MHz transducers
(Andover, Massachusetts) in a standard fashion (14). Hy-
pertrophic cardiomyopathy was diagnosed (with two-
dimensional echocardiography) by virtue of a hypertro-
phied, nondilated left ventricle (wall thickness, .13 mm) in
the absence of another cardiac or systemic disease capable of
producing the magnitude of left ventricular hypertrophy
observed (14,16). Extent and distribution of left ventricular
hypertrophy were assessed from the two-dimensional image
with the site of maximum wall thickness identified, as
previously described (14). Peak instantaneous left ventricu-
lar outflow tract gradient was estimated with continuous
wave Doppler imaging under basal conditions (17).
RESULTS
Echocardiographic diagnosis of HCM. Over the 33-
month study period, 15,137 echocardiograms were ob-
tained, and 60 were initially judged on site to be possibly
diagnostic of HCM (Fig. 1). Of these 60 patients, 16 were
excluded after careful inspection of the clinical record
revealed a history of systemic hypertension, judged sufficient
in magnitude and duration to account for the extent of left
ventricular wall thickening evident in that patient (18). Of
the remaining 44 patients (0.29%; 95% confidence interval
[CI]: 21, 39), 15 proved to have a prior diagnosis of HCM
upon retrospective review of the case records. Therefore, the
final 29 patients (0.19% of the overall study group; 95% CI:
13, 27) were patients in whom HCM was identified de novo
as part of the present study (Table 1, Fig. 1).
Patients with HCM identified de novo
INDICATIONS FOR ECHOCARDIOGRAPHIC STUDY. The 29
HCM patients identified for the first time in this study had
their diagnostic echocardiograms performed for a variety of
reasons. The primary clinical indications were: 1) recent and
initial onset of symptoms or a clinical event presumed to be
cardiovascular-related (16 patients; 55%), including three
with a cerebrovascular accident; 2) a heart murmur (11
patients; 38%), or 3) an abnormal 12-lead electrocardiogram
(ECG) performed as part of a routine examination (two
patients; 7%). Of note, of the 11 patients in whom identi-
fication of a murmur played a major role in the initial
diagnosis, five proved to have no outflow gradient on the
diagnostic echocardiogram.
CLINICAL PROFILE. At diagnosis, the patients were 16 to 87
years of age (mean 57); 14 were $60 years of age, and only
two were ,30 years (Fig. 2). Fifteen patients (51%) were
female, and all were white. At the time of diagnosis, 12
patients (41%) were judged to have no functional limitation,
although four of these had experienced transient symptoms
such as presyncope or syncope (Fig. 2); 12 others (41%) had
mild exertional symptoms (functional class II), and five
(18%) had severe symptoms and functional limitation (class
III). In eight of the latter 17 functionally limited patients,
Abbreviations and Acronyms
CI 5 confidence interval
ECG 5 electrocardiogram
HCM 5 hypertrophic cardiomyopathy
Figure 1. Flow diagram summarizing the echocardiographic find-
ings and identification of hypertrophic cardiomyopathy (HCM) in
the overall patient study group from rural, primary medical
practice. LVH 5 left ventricular hypertrophy.
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Table 1. Clinical, Demographic, Echocardiographic and Electrocardiographic Findings in 27 Patients Identified with HCM De Novo in Rural Communities
No.
Age (yr)/
Gender
Indication for
Echocardiogram
NYHA
FC
Age at
Onset of
Symptoms
(yr)
Echocardiogram Electrocardiogram Family
History
of
HCM
LV Segments (mm)
Proximal (P)/
Distal (D)*
LVOTG†
(mm Hg)
LVID
(mm)
LA
(mm) NL AF LVH ST-T
Q
Waves
Mild
HPTAVS PVS ALFW
1 45/M Routine ECG 1 None 17 — 17 P 5 D 0 40 38 0 0 0 0 1 0 0
2 54/M Symptoms 1 None 20 17 — P 5 D 0 45 41 0 0 0 1 0 0 0
3 49/F Murmur 2 25 18 17 — D . P 25 37 44 0 0 0 0 1 0 1‡
4 36/M Murmur 2 11 18 — — P . D 82 48 41 1 0 0 0 0 0 1
5 64/M Murmur 1§ None 22 — — P . D 58 56 45 0 0 0 1 1 0 0
6 82/F Murmur 3 81 19 — — P . D 64 44 42 0 0 0 0 1 1 0
7 46/M Murmur 1§ None 15 23 — D . P 0 46 45 0 0 1 0 0 0 1
8 23/F Murmur 2 21 30 29 — D . P 0 31 42 0 0 0 1 0 0 1‡
9 60/M Murmur 1 None 19 17 — P . D 20 55 41 1 0 0 0 0 1 0
10 77/F Symptoms 2 75 20 — — D . P 0 44 54 0 1 1 1 0 0 0
11 73/F Symptoms 2 68 18 — — P . D 28 37 47 0 0 0 1 0 1 0
12 37/F Symptoms 3 27 19 28 — D . P 0 35 27 0 0 1 0 1 0 1‡
13 72/F CVA 2 72 20 — — P . D 33 35 28 0 0 0 1 0 0 0
14 36/M Murmur 1 None 20 17 17 P 5 D 0 40 40 0 0 0 0 1 1 0
15 41/F Symptoms 1 None 18 — — P 5 D 0 43 34 0 0 0 1 0 0 1
16 36/F Symptoms 2 None 18 30 — D . P 0 40 39 0 0 0 1 1 0 1‡
17 58/M Symptoms 2 54 18 — — P . D 0 43 35 1 0 0 0 0 0 0
18 86/F CVA 3 83 28 — 18 P 5 D 0 36 48 0 1 0 1 1 1 0
19 78/F CVA 2 71 28 — 20 D . P 53 38 50 0 1 0 1 0 1 0
20 16/M Murmur 1 None 18 — — P . D 0 55 43 1 0 0 0 0 0 0
21 63/M Symptoms 3 62 22 22 18 P 5 D 0 51 49 0 1 0 1 0 0 1
22 78/F Symptoms 1 None 14 — 14 P 5 D 0 31 40 1 0 0 0 0 0 0
23 84/F Symptoms 3 80 18 19 — P 5 D 0 36 37 1 0 0 0 0 0 0
24 87/F Symptoms 2 Unknown 19 — — P . D 60 31 32 0 0 0 0 0 1 0
25 72/M Symptoms 2 70 22 — — P . D 35 40 41 0 0 0 1 1 1 0
26 53/M Murmur 1 None 13 — 17 P 5 D 35 47 48 0 0 0 0 1 0 0
27 54/M Murmur 1§ None 15 — — P 5 D 0 49 37 1 0 0 0 0 0 0
28 33/M Routine ECG 1§ None 20 — — D . P 0 47 39 0 0 0 1 1 0 0
29 83/F Symptoms 2 80 20 — — P 5 D 0 45 45 0 0 0 1 0 0 0
*Assessment of whether hypertrophy is predominant in the distal portion of left ventricle below mitral valve level or proximal portion cephalad to mitral valve. †Peak instantaneous left ventricular outflow gradient estimated with continuous
wave Doppler color flow imaging (17) and due to mitral valve systolic anterior motion with mitral–septal contact. ‡Includes a family history of sudden cardiac death due to hypertrophic cardiomyopathy. §Transient and occasional symptoms
of syncope or presyncope. 1 5 present; 0 5 absent; — 5 left ventricular wall thickness regarded as normal (#12 mm).
AF 5 atrial fibrillation; ALFW 5 anterolateral free wall; AVS 5 anterior ventricular septum; CVA 5 cerebrovascular accident; ECG 5 electrocardiogram; FC 5 functional class; HCM 5 hypertrophic cardiomyopathy; HPT 5
(systemic) hypertension; LA 5 left atrium; LV 5 left ventricle; LVH 5 left ventricular hypertrophy; LVID 5 left ventricular internal dimension at end-diastole; LVOTG 5 left ventricular outflow tract gradient; NL 5 normal; NYHA
5 New York Heart Association; PVS 5 posterior ventricular septum.
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the onset of symptoms had been delayed until $70 years of
age (with the oldest 83 years).
Eight of the 29 HCM patients had a history of mild
systemic hypertension judged to be insufficient to produce
the pattern or degree of left ventricular wall thickening
($18 mm) that was evident (14,16,18) (Table 1). In
addition, each of the 8 patients with associated hypertension
had clinical features consistent with HCM, such as basal left
ventricular outflow tract gradients $20 mm Hg in 6; the
other 2 nonobstructive patients had marked left ventricular
wall thicknesses of 20 mm and 28 mm. Two patients had
documented coronary artery disease, including one of those
with hypertension. Only three of the 29 patients were
known to have a family history of HCM, but systematic
pedigree analyses (3,19) were not part of this investigation.
OUTFLOW OBSTRUCTION. Based on continuous wave Dopp-
ler examination, 11 of the 29 study patients (38%) had
subaortic obstruction under basal conditions (peak instan-
taneous outflow gradients of 20 to 82 mm Hg), due to
systolic anterior motion of the mitral valve and mitral–septal
contact in 10 (anterior leaflet in 9 and posterior leaflet in 1);
8 of these patients had gradients $30 mm Hg, and 5 of
these had marked outflow obstruction (i.e., with gradients
$50 mm Hg). Eight other patients had mild-to-moderate
degrees of mitral systolic anterior motion without mitral–
septal contact which did not produce outflow obstruction
(anterior leaflet in 6 and posterior leaflet in 2). Mitral valve
leaflets were judged to be greatly elongated in 8 patients
(20), including 5 with documented outflow gradients.
LEFT VENTRICULAR HYPERTROPHY. Maximum left ventric-
ular wall thicknesses were 14 to 30 mm (mean 21), and were
$28 mm in 5 patients (17%). Analysis of the patterns of left
ventricular hypertrophy showed wall thickening confined to
one segment of the wall (i.e., anterior ventricular septum) in
14 patients (48%), involving two segments (anterior and
posterior septum or anterior septum and anterolateral free
wall) in 13 patients (45%) and diffusely involving three or
four segments (substantial portions of anterior and posterior
septum as well as anterolateral free wall) in only two patients
(7%) (Fig. 3).
The magnitude and extent of left ventricular hypertrophy
in the 29 HCM patients was compared with those of a
previously reported tertiary center HCM population (14).
With respect to the number of left ventricular wall segments
involved, the present study patients with HCM less com-
monly demonstrated diffuse hypertrophy (7% vs. 34%; p 5
0.005), and more frequently showed a mild phenotypic
expression with hypertrophy confined to one segment (48%
vs. 28%; p 5 0.036) (Fig. 3). Maximum left ventricular wall
thickness was similar in the present cohort and the tertiary
center HCM population presented for comparative pur-
poses (21 6 4 mm and 22 6 5 mm, respectively).
OTHER ECHOCARDIOGRAPHIC FINDINGS. Left atrial di-
mension was 27 to 54 mm (mean 40), and cavity enlarge-
ment (.40 mm) was evident in 17 of the 29 patients (60%).
Left ventricular end-diastolic dimension was 31 to 56 mm
(mean 42), and .55 mm in only one patient. Mitral
regurgitation was identified by color flow imaging in 13
patients (44%) and was judged as mild in eight and
moderate in five.
ELECTROCARDIOGRAMS. A variety of abnormal patterns
and abnormalities were evident on the 12-lead ECG, either
alone or in combination: 1) ST segment and T wave
alterations (n 5 14); 2) abnormally deep Q waves in inferior
and lateral leads, (n 5 9); 3) conduction abnormalities
including left or right bundle branch block and left or right
anterior hemiblock (n 5 5); 4) reduced R wave in the right
precordial leads (n 5 3), and 5) Wolff–Parkinson–White
syndrome (n 5 1). Atrial fibrillation was present in 4
patients, including 2 who presented with an embolic stroke.
Figure 2. Age distribution in years at the time of initial hypertro-
phic cardiomyopathy diagnosis. Those 12 patients without func-
tional limitation when recognized clinically are shown as stippled
portions of the bars. Figure 3. Extent of left ventricular hypertrophy (assessed by
two-dimensional echocardiography) expressed as the number of
hypertrophied left ventricular segments in each patient. The
present study patients with HCM are compared with a previously
reported hospital-based tertiary center HCM population (14).
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Increased precordial voltages consistent with a pattern of
left ventricular hypertrophy (R or S wave $25 mm; range to
38 mm) were present in only 3 patients (10%). Of note, 7
patients (24%) had ECGs judged to be within normal
limits; each of these had mild-to-moderate hypertrophy
with maximum left ventricular wall thickness ,20 mm,
most prominent in the basal portion of the wall.
Family history of HCM. Systematic pedigree analysis with
echocardiography was not performed. However, in 8 (28%)
of the 29 patients familial occurrence of HCM had been
documented in 1 or 2 relatives. In 4 of those 8 families, 1 to
3 relatives had died prematurely of HCM.
Clinical follow-up. Longitudinal clinical evaluation 3
months to 3.8 years after initial HCM diagnosis showed
that 25 of the 29 patients were alive. Of the 4 other patients,
3 died of causes definitely or probably related to HCM,
including 2 of stroke with atrial fibrillation (patients #18
and #19) and one suddenly with coexistent coronary artery
disease (patient #12); the remaining patient died of cancer.
DISCUSSION
Patient selection and HCM disease spectrum. Our over-
all perception of the clinical spectrum of HCM has been
greatly skewed by the experience of large tertiary referral
institutions located in urban centers which have dominated
the available published data (1,2,12,13). These traditional
HCM referral patterns have preferentially directed high risk
patients to such institutions, and as a result certain sub-
groups with this disease have not been adequately repre-
sented either in the published reports or within the prevail-
ing concepts of the disease spectrum. For example,
asymptomatic or mildly symptomatic older patients have
been largely absent from many published reports on HCM
(6–8). These considerations legitimately raise questions
regarding the extent to which some HCM patients may
remain unrecognized within the community. Indeed, in a
prior study (11), previously unsuspected HCM was identi-
fied by echocardiography in 0.17% of 4,111 subjects (or
about 1:500) from the general population, although the
prevalence of HCM has been reported to be much less when
limited to cases recognized clinically or at autopsy (21). In
addition, genotyping of selected HCM pedigrees has dem-
onstrated many asymptomatic patients with mild pheno-
typic expressions of HCM detectable only by echocardiog-
raphy (3,19,22) who otherwise might not be easily
identifiable clinically.
Identification of HCM in the study population. We
designed the present prospective investigation to extend
these observations and study the frequency with which
clinically unsuspected HCM could be detected by echocar-
diography in rural and general medical practice from over 60
communities within Minnesota (and Wisconsin). It has
been the mandate of our institution over the last 18 years to
provide diagnostic services to rural hospitals and clinics as
part of an outreach program, utilizing mobile units
equipped with echocardiographic instruments. Over the
17-month study period described here we identified 29
previously undiagnosed patients with HCM in about 15,000
echocardiograms. Of note, these newly recognized patients
accounted for 0.19% of the overall study group, a figure
remarkably similar to that previously reported in the general
population (11), as well as in referrals to an echocardiogra-
phy laboratory in an urban primary care setting for the
purpose of excluding cardiovascular disease (23). The pro-
portion of patients with the obstructive form of HCM (i.e.,
27% with left ventricular outflow gradients $30 mm Hg)
was similar to that generally reported in this disease (1,2).
The majority of patients in this series had symptoms or
cardiovascular events that brought them to clinical recogni-
tion and consequently stimulated an echocardiographic
study which resulted in the diagnosis of HCM for the first
time. Therefore, identification of our patient group involved
some selection bias due to the fact that most patients had
overt disease expression. However, in about 40% of our
patients it was only the fortuitous identification of a heart
murmur that triggered the diagnostic echocardiographic
studies. Therefore, it is possible that if the mobile echocar-
diography services available through our outreach program
to small rural communities had not been readily available,
the diagnosis of HCM may have been significantly delayed
or conceivably never documented in some of these cases.
Demographics and phenotypic expression. The present
HCM patients diagnosed for the first time showed a
relatively mild expression of their disease with clinical and
demographic features consistent with HCM in populations
removed from the selection bias characteristic of tertiary
referral centers (14,15,24,25). For example, 80% of the
unselected HCM patients who comprise the present study
group had experienced no functional limitation from their
disease, were 60 years of age or older at the time of
diagnosis, or both. Of those patients who developed symp-
toms, about one half were asymptomatic until $70 years of
age. Indeed, the study group is of relatively advanced age
with only 7% less than age 30 and an average age of 57 years.
These observations all underline the importance of recog-
nizing HCM as a disease compatible with advanced age and
normal longevity, and often associated with little or no
disability. Such a perspective is largely unappreciated in the
available HCM published data (1,2,26–29).
Also, in contrast to referral center populations (14), our
patients showed relatively mild phenotypic expression. Hy-
pertrophy was most frequently confined to a single segment
of the left ventricular wall (in almost 50%); more substantial
and diffusely distributed wall thickening was uncommonly
observed in ,10%. Furthermore, phenotypic expression on
the 12-lead ECG (24) was also considered to be relatively
mild, with about 25% of patients showing normal 12-lead
ECG patterns, and only about 10% demonstrating evidence
of left ventricular hypertrophy.
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